drugset / Trial / NCT07312851
A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants
RandomizedParallel-groupSingle-blindTreatment
Summary
The purpose of this study is to characterize andexanet posology and interaction between andexanet and enoxaparin post infusion in healthy participants.
Timeline
- Start
- 2026-01-19
- Primary completion
- 2026-06-22
- Completion
- 2026-06-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Andexanet alfa | Protein / enzyme biologic | — | Intravenous |
| Subject | Enoxaparin sodium | Other / unclassified | — | Subcutaneous |
| Background | Apixaban | Small molecule | 5 mg | Oral |
| Background | Rivaroxaban | Other / unclassified | 20 mg | Oral |
Indications
No indication recorded.